82 results
S-3
EX-4.6
ALLO
Allogene Therapeutics Inc
14 Mar 24
Shelf registration
5:21pm
in this Indenture or in any of the Securities or implied therefrom; and that any and all such
personal liability of every name and nature, either … read such covenant or condition; (ii) a brief statement as to the nature and scope of the examination or investigation upon which the statements
S-3
ALLO
Allogene Therapeutics Inc
14 Mar 24
Shelf registration
5:21pm
that are not strictly historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act, and within the meaning … will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship.
We may sell securities directly or through agents
POSASR
x24bm0
14 Mar 24
Automatic shelf registration (post-effective amendment)
4:51pm
8-K
EX-99.1
a4dtmwvyladnl
14 Mar 24
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023
4:10pm
8-K
z499l74guv79m
16 Feb 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
8:30am
8-K
0sk3t7580
5 Jan 24
Entry into a Material Definitive Agreement
8:00am
424B5
sy84r634
2 Nov 23
Prospectus supplement for primary offering
4:41pm
8-K
EX-99.1
pv3n6l16lct2py95ibi
2 Nov 23
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
4:03pm
8-K
EX-99.1
d8q561
2 Aug 23
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
4:04pm